Evercore ISI Lowers Humana (NYSE:HUM) Price Target to $180.00

Humana (NYSE:HUM) had its price objective reduced by stock analysts at Evercore ISI from $260.00 to $180.00 in a research report issued on Thursday,MarketScreener reports. Evercore ISI’s price target would suggest a potential downside of 2.13% from the company’s current price.

HUM has been the subject of a number of other research reports. Sanford C. Bernstein reissued an “outperform” rating and set a $344.00 price objective on shares of Humana in a research report on Tuesday, January 6th. Royal Bank Of Canada lowered Humana from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $322.00 to $189.00 in a report on Thursday. Wells Fargo & Company downgraded Humana from an “overweight” rating to a “cautious” rating in a research note on Wednesday, January 7th. Morgan Stanley set a $146.00 target price on shares of Humana in a research note on Thursday. Finally, Jefferies Financial Group lowered their price target on shares of Humana from $313.00 to $310.00 and set a “buy” rating on the stock in a report on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $239.46.

Humana Trading Up 2.8%

Humana stock opened at $183.92 on Thursday. Humana has a 52-week low of $169.61 and a 52-week high of $315.35. The company has a market cap of $22.12 billion, a P/E ratio of 18.73, a P/E/G ratio of 1.99 and a beta of 0.44. The company has a quick ratio of 2.02, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The business has a 50-day simple moving average of $244.65 and a two-hundred day simple moving average of $260.85.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Analysts predict that Humana will post 16.47 EPS for the current year.

Institutional Trading of Humana

Hedge funds have recently made changes to their positions in the business. Revolve Wealth Partners LLC bought a new stake in shares of Humana in the 4th quarter valued at approximately $202,000. Woodline Partners LP lifted its stake in shares of Humana by 460.0% during the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after acquiring an additional 8,372 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Humana by 53.7% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after acquiring an additional 452 shares during the period. Callan Family Office LLC bought a new position in Humana in the 2nd quarter valued at $298,000. Finally, IFP Advisors Inc lifted its position in shares of Humana by 45.5% during the second quarter. IFP Advisors Inc now owns 799 shares of the insurance provider’s stock worth $195,000 after purchasing an additional 250 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary?care network (~82 owned/affiliated clinics and >80,000 patients in value?based programs) which expands Humana’s senior-focused, value?based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary?care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value?based care capacity — a long?term growth catalyst if Humana can scale clinics and convert MA members to higher?margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near?term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near?term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth?quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near?term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.